4-aminopyridine has been researched along with Kidney Diseases in 2 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mean terminal disposition half-life was 6." | 2.75 | Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. ( Henney, H; Marbury, T; Smith, W; Swan, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samara, E | 1 |
| Winkle, P | 1 |
| Pardo, P | 1 |
| Henney, HR | 1 |
| Way, SL | 1 |
| Brown, E | 1 |
| Lee, A | 1 |
| Blight, AR | 1 |
| Smith, W | 1 |
| Swan, S | 1 |
| Marbury, T | 1 |
| Henney, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for 4-aminopyridine and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.
Topics: 4-Aminopyridine; Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Area Under Curve; Body | 2014 |
Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Creatinine; Delayed-Action Preparations; Drug Admin | 2010 |